Video

Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy

Source: Invetech

One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures.

Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.
 
Invetech configures scalable automated GMP manufacturing systems for cell-based products. This includes our formulation and fill automated systems and our (to be launched) counterflow centrifuge product (CFC).
 
Our formulation and fill systems focus on the formulation of large-scale culture media, cell products for cryopreservation, automated bag-filling of cell products (both autologous and allogeneic) and packaging of viral vector products.

VIEW THE VIDEO!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: